Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350

Journal of Virology

Volumn 82, Issue 22, 2008, Pages 11217-11227

  Young, Kendra A ^a   Herbert, Andrew P ^b   Barlow, Paul N ^b   Holers, V Michael ^a   Hannan, Jonathan P ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARAGINE; ASPARTIC ACID; COMPLEMENT COMPONENT C3D RECEPTOR; GLUTAMIC ACID; GLYCOPROTEIN GP 350; ISOLEUCINE; LYSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 72A1; PHYCOERYTHRIN; THREONINE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; MUTANT PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; GENE MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; AMINO ACID SUBSTITUTION; CHEMICAL STRUCTURE; GENETICS; HUMAN; METABOLISM; MISSENSE MUTATION; PHYSIOLOGY; POINT MUTATION; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN TERTIARY STRUCTURE; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE; VIRUS ATTACHMENT;

HUMAN HERPESVIRUS 4;

AMINO ACID SUBSTITUTION; BINDING SITES; CELL LINE, TUMOR; HERPESVIRUS 4, HUMAN; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; MUTATION, MISSENSE; POINT MUTATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, COMPLEMENT 3D; VIRAL MATRIX PROTEINS; VIRUS ATTACHMENT;

EID: 55549083164     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01673-08     Document Type: Article

References (47)

1. Asokan, R., J. Hua, K. A. Young, H. J. Gould, J. P. Hannan, D. M. Kraus, G. Szakonyi, G. J. Grundy, X. S. Chen, M. K. Crow, and V. M. Holers. 2006. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus. J. Immunol. 177:383-394.
2. Aubry, J. P., S. Pochon, J. F. Gauchat, A. Nueda-Marin, V. M. Holers, P. Graber, C. Siegfried, and J. Y. Bonnefoy. 1994. CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21. J. Immunol. 152:5806-5813.
3. Aubry, J. P., S. Pochon, P. Graber, K. U. Jansen, and J. Y. Bonnefoy. 1992. CD21 is a ligand for CD23 and regulates IgE production. Nature 358:505-507.
4. Beisel, C., J. Tanner, T. Matsuo, D. Thorley-Lawson, F. Kezdy, and E. Kieff. 1985. Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene. J. Virol. 54:665-674.
5. Boackle, S. A., V. M. Holers, X. Chen, G. Szakonyi, D. R. Karp, E. K. Wakeland, and L. Morel. 2001. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 15:775-785.
6. Cohen, J. I. 2005. Clinical aspects of Epstein-Barr virus infection, p. 35-54. In E. S. Robertson (ed.), Epstein-barr virus, Horizon Scientific Press, Wymondham, United Kingdom.
7. Delcayre, A. X., F. Salas, S. Mathur, K. Kovats, M. Lotz, and W. Lernhardt. 1991. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor. EMBO J. 10:919-926.
8. Dominguez, C., R. Boelens, and A. M. Bonvin. 2003. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J. Am. Chem. Soc. 125:1731-1737.
9. Fingeroth, J. D., J. J. Weis, T. F. Tedder, J. L. Strominger, P. A. Biro, and D. T. Fearon. 1984. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. USA 81:4510-4514.
10. Frade, R., M. Barel, B. Ehlin-Henriksson, and G. Klein. 1985. gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc. Natl. Acad. Sci. USA 82:1490-1493.
11. Gilbert, H. E., J. T. Eaton, J. P. Hannan, V. M. Holers, and S. J. Perkins. 2005. Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study. J. Mol. Biol. 346:859-873.
12. Guthridge, J. M., J. K. Rakstang, K. A. Young, J. Hinshelwood, M. Aslam, A. Robertson, M. G. Gipson, M. R. Sarrias, W. T. Moore, M. Meagher, D. Karp, J. D. Lambris, S. J. Perkins, and V. M. Holers. 2001. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg. Biochemistry 40:5931-5941.
13. Guthridge, J. M., K. Young, M. G. Gipson, M. R. Sarrias, G. Szakonyi, X. S. Chen, A. Malaspina, E. Donoghue, J. A. James, J. D. Lambris, S. A. Moir, S. J. Perkins, and V. M. Holers. 2001. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface. J. Immunol. 167:5758-5766.
14. Haan, K. M., S. K. Lee, and R. Longnecker. 2001. Different functional domains in the cytoplasmic tail of glycoprotein B are involved in Epstein-Barr virus-induced membrane fusion. Virology 290:106-114.
15. Haddad, R. S., and L. M. Hutt-Fletcher. 1989. Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells. J. Virol. 63:4998-5005.
16. Hannan, J. P., G. Szakonyi, R. Asokan, X. Chen, and V. M. Holers. 2005. Complement receptor CR2/CD21 and CR2-C3d complexes, p. 143-160. In D. Morikis and J. D. Lambris (ed.), Structural biology of the complement system, CRC Press, Boca Raton, FL.
17. Hannan, J. P., K. A. Young, J. M. Guthridge, R. Asokan, G. Szakonyi, X. S. Chen, and V. M. Holers. 2005. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d. J. Mol. Biol. 346:845-858.
18. Hannan, J. P., K. A. Young, A. P. Herbert, X. S. Chen, P. N. Barlow, and V. M. Holers. 2007. Characterizing the complement receptor type 2 (CR2)-Epstein-Barr virus interaction: a site-directed mutagenesis and molecular docking approach. Mol. Immunol. 44:3929.
19. Hutt-Fletcher, L. M. 2007. Epstein-Barr virus entry. J. Virol. 81:7825-7832.
20. Jackman, W. T., K. A. Mann, H. J. Hoffmann, and R. R. Spaete. 1999. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine 17:660-668.
21. Janz, A., M. Oezel, C. Kurzeder, J. Mautner, D. Pich, M. Kost, W. Hammerschmidt, and H. J. Delecluse. 2000. Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J. Virol. 74:10142-10152.
22. Johannsen, E., M. Luftig, M. R. Chase, S. Weicksel, E. Cahir-McFarland, D. Illanes, D. Sarracino, and E. Kieff. 2004. Proteins of purified Epstein-Barr virus. Proc. Natl. Acad. Sci. USA 101:16286-16291.
23. Kalli, K. R., J. M. Ahearn, and D. T. Fearon. 1991. Interaction of iC3b with recombinant isotypic and chimeric forms of CR2. J. Immunol. 147:590-594.
24. Kirkitadze, M. D., and P. N. Barlow. 2001. Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol. Rev. 180:146-161.
25. Mackett, M., C. Cox, S. D. Pepper, J. F. Lees, B. A. Naylor, N. Wedderburn, and J. R. Arrand. 1996. Immunisation of common marmosets with vaccinia virus expressing Epstein-Barr virus (EBV) gp340 and challenge with EBV. J. Med. Virol. 50:263-271.
26. Martin, D. R., A. Yuryev, K. R. Kalli, D. T. Fearon, and J. M. Ahearn. 1991. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2. J. Exp. Med. 174:1299-1311.
27. Menet, A., C. Speth, C. Larcher, W. M. Prodinger, M. G. Schwendinger, P. Chan, M. Jager, F. Schwarzmann, H. Recheis, M. Fontaine, and M. P. Dierich. 1999. Epstein-Barr virus infection of human astrocyte cell lines. J. Virol. 73:7722-7733.
28. Molesworth, S. J., C. M. Lake, C. M. Borza, S. M. Turk, and L. M. Hutt-Fletcher. 2000. Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. J. Virol. 74:6324-6332.
29. Morikis, D., and J. D. Lambris. 2004. The electrostatic nature of C3d-complement receptor 2 association. J. Immunol. 172:7537-7547.
30. Nemerow, G. R., R. A. Houghten, M. D. Moore, and N. R. Cooper. 1989. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 56:369-377.
31. Nemerow, G. R., C. Mold, V. K. Schwend, V. Tollefson, and N. R. Cooper. 1987. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J. Virol. 61:1416-1420.
32. Nemerow, G. R., J. J. Mullen III, P. W. Dickson, and N. R. Cooper. 1990. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection. J. Virol. 64:1348-1352.
33. Nemerow, G. R., R. Wolfert, M. E. McNaughton, and N. R. Cooper. 1985. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J. Virol. 55:347-351.
34. Prota, A. E., D. R. Sage, T. Stehle, and J. D. Fingeroth. 2002. The crystal structure of human CD21: implications for Epstein-Barr virus and C3d binding. Proc. Natl. Acad. Sci. USA 99:10641-10646.
35. Rickinson, A. B., and E. Kieff. 2007. Epstein-Barr virus, p. 2655-2700. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
36. Sarrias, M. R., S. Franchini, G. Canziani, E. Argyropoulos, W. T. Moore, A. Sahu, and J. D. Lambris. 2001. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220. J. Immunol. 167:1490-1499.
37. Soares, D. C., and P. N. Barlow. 2005. Complement control protein modules in the regulators of complement activation, p. 19-62. In D. Morikis and J. D. Lambris (ed.), Structural biology of the complement system, CRC Press, Boca Raton, FL.
38. Sokal, E. M., K. Hoppenbrouwers, C. Vandermeulen, M. Moutschen, P. Leonard, A. Moreels, M. Haumont, A. Bollen, F. Smets, and M. Denis. 2007. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 196:1749-1753.
39. Szakonyi, G., J. M. Guthridge, D. Li, K. Young, V. M. Holers, and X. S. Chen. 2001. Structure of complement receptor 2 in complex with its C3d ligand. Science 292:1725-1728.
40. Szakonyi, G., M. G. Klein, J. P. Hannan, K. A. Young, R. Z. Ma, R. Asokan, V. M. Holers, and X. S. Chen. 2006. Structure of the Epstein-Barr virus major envelope glycoprotein. Nat. Struct. Mol. Biol. 13:996-1001.
41. Tanner, J., Y. Whang, J. Sample, A. Sears, and E. Kieff. 1988. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. J. Virol. 62:4452-4464.
42. Thorley-Lawson, D. A., and K. Geilinger. 1980. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc. Natl. Acad. Sci. USA 77:5307-5311.
43. Urquiza, M., R. Lopez, H. Patino, J. E. Rosas, and M. E. Patarroyo. 2005. Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells. J. Biol. Chem. 280:35598- 35605.
44. van Dijk, A. D., S. J. de Vries, C. Dominguez, H. Chen, H. X. Zhou, and A. M. Bonvin. 2005. Data-driven docking: HADDOCK's adventures in CAPRI. Proteins 60:232-238.
45. Weis, J. J., T. F. Tedder, and D. T. Fearon. 1984. Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc. Natl. Acad. Sci. USA 81:881-885.
46. Young, K. A., X. S. Chen, V. M. Holers, and J. P. Hannan. 2007. Isolating the Epstein-Barr virus (EBV) GP350/220 binding site on complement receptor type 2 (CR2/CD21). J. Biol. Chem. 282:36614-36625.
47. Zhang, L., B. Mallik, and D. Morikis. 2007. Immunophysical exploration of C3d-CR2(CCP1-2) interaction using molecular dynamics and electrostatics. J. Mol. Biol. 369:567-583.